Borneo Journal of Pharmacy https://journal.umpr.ac.id/index.php/bjop <p style="text-align: justify;"><strong>Title: </strong>Borneo Journal of Pharmacy<br /><strong>ISSN: </strong><a href="https://portal.issn.org/resource/ISSN/2621-4814">2621-4814</a> (Online)<br /><strong>Accreditation: <a href="https://sinta.kemdikbud.go.id/journals/profile/5983">SINTA 2</a></strong> until 2025 by the Minister of Research and Technology/National Research and Innovation Agency, Indonesia No: <strong><a href="https://storage.googleapis.com/arjuna-files/file/info/Hasil_Penetapan_Akreditasi_Jurnal_Periode_2_Tahun_2020.pdf">148/M/KPT/2020</a></strong>.<br /><strong>Subject: </strong>Pharmacy and Pharmaceutical Sciences<br /><strong>Frequency: </strong>Quarterly (4 issues per year in February, May, August, and November) onward <strong>February 2020</strong><br /><strong>Indexed at: </strong><a href="https://assets.ctfassets.net/o78em1y1w4i4/7DqHvOd6Wk1HPaSRTcncly/75fa577da3531231ffd853b4f054d1be/Embase-Jan-2024-journals-list.xlsx">EMBASE</a>, <a href="https://sinta.kemdikbud.go.id/journals/profile/5983">SINTA 2</a>,<strong> </strong><a href="https://app.dimensions.ai/discover/publication?search_mode=content&amp;and_facet_source_title=jour.1365735">Dimensions</a>, <a href="https://doaj.org/toc/2621-4814">DOAJ</a>, <a href="https://v2.sherpa.ac.uk/id/publication/37313">SHERPA RoMEO</a>, <a href="https://search.crossref.org/?q=+2621-4814&amp;from_ui=yes">Crossref,</a> <a href="http://journalseeker.researchbib.com/view/issn/2621-4814">ResearchBib</a>, <a href="https://scholar.google.com/citations?hl=en&amp;user=R7G787AAAAAJ">Google Scholar,</a> <a href="https://garuda.kemdikbud.go.id/journal/view/35722">GARUDA</a>, and <a href="https://journal.umpr.ac.id/index.php/bjop/indexing">more</a><br /><strong>DOI: </strong><a href="https://doi.org/10.33084/bjop">10.33084/bjop</a><br /><strong>Archive preservation: </strong><a href="https://onesearch.id/Search/Results?filter[]=repoId:IOS6026">Indonesia OneSearch</a>,<strong> </strong><a href="https://garuda.kemdikbud.go.id/journal/view/35722">GARUDA</a>, and <a href="https://scholar.archive.org/search?q=Borneo+journal+of+pharmacy&amp;offset=0">Internet Archive Scholar</a><br /><strong>Publisher: </strong><a href="https://lp2m.umpr.ac.id/" target="_blank" rel="noopener">Institute for Research and Community Services</a> <a href="https://umpr.ac.id" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a> in collaboration with the <a href="https://drive.google.com/file/d/1LwF3LBukGCzkwwNuZOu96737Os8JnEh8/view?usp=share_link" target="_blank" rel="noopener">Central Board of the Indonesian Pharmacists Association <em>(Pengurus Pusat Ikatan Apoteker Indonesia)</em></a> <br /><strong>Editor in Chief: </strong><a href="https://orcid.org/0000-0002-0727-4392">Mohammad Rizki Fadhil Pratama</a></p> <p style="text-align: justify;"><strong>Borneo Journal of Pharmacy</strong> (<em>Borneo J Pharm</em>, ISSN: <em><a href="https://portal.issn.org/resource/ISSN/2621-4814">2621-4814</a></em> (online)) is an international scientific platinum open-access journal managed by the <strong><a title="Department of Pharmacy Faculty of Health Science" href="https://fik.umpr.ac.id/program-studi/d3-farmasi/" target="_blank" rel="noopener">Department of Pharmacy Faculty of Health Science</a> <a href="https://umpr.ac.id" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a></strong> in collaboration with the <a href="https://drive.google.com/file/d/1LwF3LBukGCzkwwNuZOu96737Os8JnEh8/view?usp=share_link" target="_blank" rel="noopener"><strong>Central Board of the Indonesian Pharmacists Association <em>(Pengurus Pusat Ikatan Apoteker Indonesia)</em></strong></a> and published four times a year (in February, May, August, and November) onward February 2020 by <strong><a href="https://lp2m.umpr.ac.id/" target="_blank" rel="noopener">Institute for Research and Community Services</a> <a href="https://umpr.ac.id" target="_blank" rel="noopener">Universitas Muhammadiyah Palangkaraya</a></strong>. <strong>Borneo Journal of Pharmacy</strong> accepts scientific articles as <strong>original research articles</strong>, <strong>short communication</strong>, <strong>reviews,</strong> and <strong>mini-reviews</strong> from anyone without any discrimination, as long as they submit articles that meet scientific principles.</p> <p style="text-align: justify;">As a distinctive feature, the <strong>Borneo Journal of Pharmacy</strong> prioritizes research articles conducted on the <strong>island of Borneo</strong> (consisting of <strong>Indonesia</strong>, <strong>Malaysia</strong>, and <strong>Brunei Darussalam</strong>) and those conducted by researchers from institutions on the island of Borneo. In every volume, there are always articles written by authors from the island of Borneo. However, articles from researchers outside the island of Borneo are also welcome.</p> <p style="text-align: justify;"><strong>Borneo Journal of Pharmacy </strong>publishes various scientific articles covering <strong>Pharmacy and Pharmaceutical Sciences</strong> in the fields but not limited to <strong>Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutical, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, Clinical-Community Pharmacy, Management Pharmacy, </strong>and <strong>Pharmaceutical Education.</strong></p> en-US <p style="text-align: justify;">This work is licensed under a <a href="https://creativecommons.org/licenses/by-sa/4.0/" rel="license">Creative Commons Attribution-ShareAlike 4.0 International License</a>.</p> <p style="text-align: justify;">Authors continue to retain the copyright to the article if the article is published in the <strong>Borneo Journal of Pharmacy</strong>. They will also retain the publishing rights to the article without any restrictions.</p> <p style="text-align: justify;">Authors who publish in this journal agree to the following terms:</p> <ol> <li class="show" style="text-align: justify;">Any article on the copyright is retained by the author(s).</li> <li class="show" style="text-align: justify;">The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.</li> <li class="show" style="text-align: justify;">Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.</li> <li class="show" style="text-align: justify;">Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.</li> <li class="show" style="text-align: justify;">The article and any associated published material are distributed under the <a href="http://creativecommons.org/licenses/by-sa/4.0/">Creative Commons Attribution-ShareAlike 4.0 International License</a>.</li> </ol> mohammadrizkifadhilpratama@umpr.ac.id (Mohammad Rizki Fadhil Pratama) bjop@umpr.ac.id (Syahrida Dian Ardhany) Fri, 30 Aug 2024 00:00:00 +0000 OJS 3.2.1.4 http://blogs.law.harvard.edu/tech/rss 60 Formulation of Nutraceutical Jelly Candy from a Combination of Cucurbita moschata Puree and Averrhoa carambola Juice as Antioxidant https://journal.umpr.ac.id/index.php/bjop/article/view/4640 <p>Nutraceutical candy jellies are gaining popularity as a potential approach to deliver antioxidants in a palatable form. This study investigated the antioxidant activity of <em>Cucurbita moschata</em> puree combined with <em>Averrhoa carambola</em> juice, formulated into jelly candies. Design-Expert software V.13 was used to optimize the jelly candy base formula. The combined <em>C. moschata</em> puree and <em>A. carambola</em> juice exhibited strong antioxidant activity (IC<sub>50</sub> = 29.580 ppm) at variation V1. The optimal base formula B3 consisted of 12% gelatin and 4% carrageenan. The formulated jelly candy possessed very strong antioxidant activity (IC<sub>50</sub> = 44.771 ppm). These findings suggest the potential of <em>C. moschata</em> puree and <em>A. carambola</em> juice as ingredients in functional jelly candies.</p> Alya Fajrina Soraya, Andi Tenri Kawareng, Risna Agustina Copyright (c) 2024 Alya Fajrina Soraya, Andi Tenri Kawareng, Risna Agustina https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/4640 Fri, 30 Aug 2024 00:00:00 +0000 Ethnomedicine Study of Medicinal Plants for Therapy of Elderly Sleep Disorders in Tengger Tribe https://journal.umpr.ac.id/index.php/bjop/article/view/7272 <p>Ethnomedicine offers valuable insights into plant-based therapies, potentially leading to the discovery of novel drugs. Sleep disturbances, including difficulty falling asleep, maintaining sleep, and early morning awakening, are prevalent among the elderly population and can significantly worsen Alzheimer's disease progression. This study explores the medicinal plants utilized by the Tengger tribe's elderly population for treating sleep disorders. Employing a mixed-methods approach, the study involved qualitative data collection through snowball sampling and in-depth interviews with 99 elderly participants and three traditional healers of the Tengger tribe. Quantitative data was obtained through questionnaires administered during field surveys. Participants were selected based on specific criteria: elderly individuals over 60 years of age, native Tengger tribe members with a history of using medicinal plants for sleep disorders; traditional healers were required to be native Tengger tribe members with knowledge passed down through generations. The study identified a total of 11 medicinal plants used for sleep disorders. Five plant species emerged as the most dominant based on the highest citation value (FC) analysis: kale (<em>Ipomoea reptans</em>), agarwood (<em>Aquilaria malaccensis</em>), sintok (<em>Cinnamomum</em> <em>sintoc</em>), Broadleaf plantain (<em>Plantago major</em>), and soursop (<em>Annona</em> <em>muricata</em>). The most commonly used plant parts were leaves, bark, and roots. Traditional preparation methods included boiling and burning the plant materials. Notably, knowledge of these medicinal plants is primarily transmitted orally within the community. Our findings highlight five medicinal plants employed by the Tengger elderly to manage sleep disorders, with limited documented evidence of their efficacy.</p> Devanus Lahardo, Wiwied Ekasari, Aty Widyawaruyanti Copyright (c) 2024 Devanus Lahardo, Wiwied Ekasari, Aty Widyawaruyanti https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/7272 Fri, 30 Aug 2024 00:00:00 +0000 In Vitro Evaluation of Prebiotic Potential of Red Ginger (Zingiber officinale var. rubrum) Rhizome Ethanol Extract on Lactobacillus acidophilus and Escherichia coli https://journal.umpr.ac.id/index.php/bjop/article/view/6029 <p>Prebiotics, including carbohydrates and phenols, promote beneficial gut bacteria (probiotics). Red ginger (<em>Zingiber officinale</em> var. <em>rubrum)</em> rhizomes, rich in these compounds, have been traditionally used in medicine but their prebiotic potential remains unexplored. This study investigated the <em>in vitro</em> prebiotic effects of <em>Z. officinale</em> var. <em>rubrum</em> rhizomes on <em>Lactobacillus acidophilus</em> (beneficial) and <em>Escherichia coli</em> (opportunistic) bacteria. Prebiotic activity was assessed using a turbidimetric method, measuring bacterial growth via UV-Vis spectrophotometry at 600 nm. The prebiotic index and percentage inhibition were calculated to evaluate the impact on bacterial growth. Additionally, total phenol content was determined using the Folin-Ciocalteu method. Results indicate that <em>Z. officinale</em> var. <em>rubrum</em> rhizomes exhibit prebiotic properties, stimulating <em>L. acidophilus</em> growth (prebiotic index of 156.035 and percentage inhibition value of -153.128%) while inhibiting <em>E. coli</em> growth (54.343% inhibition). The rhizomes contained 31.15 mg GAE/g extract of total phenols and 23.55% carbohydrates. These findings suggest that <em>Z. officinale</em> var. <em>rubrum</em> rhizomes possess prebiotic potential, warranting further investigation for potential applications in gut health management.</p> Fadil Rido Gumelar, Farendina Suarantika, Bertha Rusdi Copyright (c) 2024 Fadil Rido Gumelar, Farendina Suarantika, Bertha Rusdi https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6029 Fri, 30 Aug 2024 00:00:00 +0000 Structure Modification of Cinnamic Acid to (E)-1-(3,4-dihydroisoquinoline-2(1H)-yl)-3-phenylprop-2-en-1-one and Antioxidant Activity Test by DPPH Method https://journal.umpr.ac.id/index.php/bjop/article/view/6163 <p>Antioxidants can protect cells from free radical damage by stabilizing them. One of the compounds that has antioxidant activity is cinnamic acid. Cinnamic acid and its derivatives have several activities: antibacterial, anticancer, and antioxidant. However, the ability of cinnamic acid to capture free radicals is still relatively low. One of the efforts that can be made to increase the antioxidant activity of cinnamic acid is to modify its structure. Structure modification is an effort to improve the pharmacological activity of a compound through chemical synthesis reactions. The cinnamic acid structure can be modified by changing the carboxylic -OH group into an amine group through an N-atom acylation reaction. This study was conducted by reacting cinnamoyl chloride (<strong>1a</strong>), which is a cinnamic acid derivative with 1,2,3,4-tetrahydroisoquinoline (<strong>2b</strong>) which is a compound of isoquinoline group to produce (<em>E</em>)-1-(3,4-dihydroisoquinoline-2(1H)-yl)-3-phenylprop-2-en-1-one (<strong>3b</strong>) and then tested for antioxidant activity using DPPH method. The resulting product compound was yellow crystals with a yield of 81.56%. The antioxidant activity produced by the product is more significant than that of cinnamic acid compounds at the same concentration.</p> Dian Agung Pangaribowo, Fathunnisa Fathunnisa, Ari Satia Nugraha, Ayik Rosita Puspaningtyas, Indah Purnama Sary Copyright (c) 2024 Dian Agung Pangaribowo, Fathunnisa Fathunnisa, Ari Satia Nugraha, Ayik Rosita Puspaningtyas, Indah Purnama Sary https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6163 Fri, 30 Aug 2024 00:00:00 +0000 Affinity of Nintedanib Towards New Candidate Target for Idiopathic Pulmonary Fibrosis https://journal.umpr.ac.id/index.php/bjop/article/view/7218 <p style="text-align: justify;">Idiopathic pulmonary fibrosis (IPF) is a progressive disease due to aggregation of fibroblasts on lung parenchyma. Nintedanib, an indolinone-derived tyrosine kinase inhibitor (TKi) has been approved for the treatment of IPF and it is a well-known inhibitor of platelet-derived growth factor (PDGF) receptor-α and -β, fibroblast growth factor (FGF) receptor-1–3 and vascular endothelial growth factor (VEGF) receptor-1–3. This study aims to evaluate the binding interaction between new therapeutic protein candidates for IPF such as autotaxin, galectin-3, interleukin-13, chitotriosidase-1, JNK, RhoE-ROCK-1, ROCK-2 against nintedanib. In this investigation we predicted, computed, and analyzed the binding interactions of the drug nintedanib using an <em>in silico</em> approach called molecular docking. Our docking studies demonstrated that RhoE-ROCK1 and autotaxin showed strong binding affinities towards nintedanib compared to known targets such as VEGFR2 and FGFR1. We can therefore hypothesize a further contribution of nintedanib to the improvement of pathology due to its affinity towards new targets in the pathogenesis of IPF. The next step will be to evaluate the effects of this affinity <em>in vitro</em> on specific cellular models.</p> Hari Baskar Balasubramanian, Sima Biswas, Maria Talmon, Filippo Patrucco, Piero Emilio Balbo, Luigia Grazia Fresu, Angshuman Bagchi Copyright (c) 2024 Hari Baskar Balasubramanian, Sima Biswas, Maria Talmon, Filippo Patrucco, Piero Emilio Balbo, Luigia Grazia Fresu, Angshuman Bagchi https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/7218 Fri, 30 Aug 2024 00:00:00 +0000 Thiourea Derivatives as Estrogen Receptor Alpha Inhibitors for Breast Cancer Therapy: An In Silico Evaluation with ADMET Prediction and Molecular Docking https://journal.umpr.ac.id/index.php/bjop/article/view/7396 <p>Breast cancer remains a significant public health concern, necessitating the discovery of novel therapeutic agents. This study investigates the potential of thiourea derivatives, specifically HU, HTMX, and BMPTU compounds, as estrogen receptor alpha (ERα) inhibitors using computational approaches. Drug-likeness assessments using Lipinski's Ro5 confirmed the oral bioavailability of all compounds. Additionally, ADMET analysis indicated favorable pharmacokinetic properties, with minimal metabolic interactions and acceptable safety profiles, except for BMPTU2, which showed potential hepatotoxicity. Molecular docking simulations revealed strong binding affinities between BMPTU derivatives, particularly BMPTU2, BMPTU3, and BMPTU4, and key ERα residues. These interactions suggest their potential as ERα modulators, warranting further <em>in silico</em> and experimental validation. In conclusion, the findings highlight the potential of BMPTU derivatives, especially BMPTU2, BMPTU3, and BMPTU4, as promising lead compounds for developing novel ERα-targeted breast cancer therapies. Further optimization and validation are crucial to fully elucidate their therapeutic potential.</p> Hestining Puspaweni, Bambang Tri Purwanto, Tri Widiandani, Siswandono Siswodihardjo, M. Artabah Muchlisin Copyright (c) 2024 Hestining Puspaweni, Bambang Tri Purwanto, Tri Widiandani, Siswandono Siswodihardjo, M. Artabah Muchlisin https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/7396 Fri, 30 Aug 2024 00:00:00 +0000 Effects of Switching Dose, Dose Variation, and Warfarin Interaction on the Incidence of Stroke Recurrence in Stroke Patients with Atrial Fibrillation https://journal.umpr.ac.id/index.php/bjop/article/view/6603 <p>Atrial fibrillation (AF) significantly increases the risk of stroke, necessitating anticoagulation therapy. Warfarin, a commonly prescribed anticoagulant regimen, requires careful monitoring to ensure patient safety. This study aimed to assess the impact of dose switching, dose variation, and potential interactions with warfarin on the incidence of stroke recurrence in stroke patients with AF. The study retrospectively analyzed the treatment records of stroke patients with AF in outpatient settings over one year. The subjects comprised 314 patients who received warfarin prescriptions at two Indonesian Hospitals from January 1, 2015, to December 31, 2019. Out of these patients, 50 had recorded data regarding dose adjustments, variations, and interactions. They were divided into two groups: a case group (n=11) with stroke recurrence and a control group (n=39) without recurrence. Statistical analysis, including chi-square tests and odds ratio calculations, revealed that both warfarin dose switching (OR=7.6) and dose variation (OR=6.6) significantly influenced the incidence of stroke recurrence. It implies that inconsistencies or alterations in warfarin dosing substantially elevate the likelihood of experiencing another stroke, potentially due to inadequate anticoagulation leading to clot formation. Interestingly, the analysis of drug interactions did not significantly impact stroke recurrence. In summary, the recurrence of stroke in patients with AF is notably influenced by warfarin dose adjustments and variations rather than drug interactions. This study highlights the critical importance of precise dosing strategies and vigilant monitoring to enhance the efficacy of anticoagulant therapy in this high-risk population.</p> Lailla Affianti Fauzi, Erna Kristin, Rizaldy Taslim Pinzon, Bernadeta Margareta Wara Kushartanti, Novita Intan Arovah Copyright (c) 2024 Lailla Affianti Fauzi, Erna Kristin, Rizaldy Taslim Pinzon, Bernadeta Margareta Wara Kushartanti, Novita Intan Arovah https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6603 Fri, 30 Aug 2024 00:00:00 +0000 Antioxidant Activity, Total Phenolics, and Total Flavonoids Content of Bajakah Tampala (Spatholobus littoralis): The Indigenous Herbal Medicine from Kalimantan https://journal.umpr.ac.id/index.php/bjop/article/view/6609 <p>Bajakah tampala (<em>Spatholobus littoralis</em>), a medicinal plant traditionally used in Indonesia, particularly on Kalimantan Island, has garnered interest for its potential health benefits. However, scientific evidence remains scarce. This study investigated the antioxidant activity of <em>S. littoralis</em> extract and its total phenolic and flavonoid content. Ethanol extraction and evaporation were used to prepare the extract. The DPPH method assessed antioxidant activity, while Folin–Ciocalteu and AlCl<sub>3</sub> complexation methods quantified total phenolics and flavonoids, respectively. The <em>S. littoralis</em> extract exhibited strong antioxidant activity with an IC<sub>50</sub> value of 54.19 ± 8.15 µg/mL. Additionally, the extract contained substantial levels of phenolics (0.649 ± 0.026% GAE) and flavonoids (1.084 ± 0.043% QE). These findings suggest a link between the high phenolic and flavonoid content of <em>S. littoralis</em> extract and its observed strong antioxidant activity.</p> Nurkhasanah Mahfudh, Habib Basyanur Murdi, Dwi Utami, Mustofa Ahda, Siti Nashihah, Andika Andika Copyright (c) 2024 Nurkhasanah Mahfudh, Habib Basyanur Murdi, Dwi Utami, Mustofa Ahda, Siti Nashihah, Andika Andika https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6609 Fri, 30 Aug 2024 00:00:00 +0000 A Pre-Post Survey Analysis on Pharmacy Students' Perceptions of Pharmacist Roles in the Pharmaceutical Industry https://journal.umpr.ac.id/index.php/bjop/article/view/6791 <p>The pharmaceutical industry is undergoing rapid evolution, characterized by a complex regulatory landscape and the need for diverse skill sets. This study aimed to assess pharmacy students’ perceptions of the pharmaceutical industry and the impact of a dedicated seminar on their career aspirations and knowledge. A pre-post online survey was administered to 55 undergraduate pharmacy students at the National Pharmacy Seminar 2024, hosted by Jakarta Global University. Data were analyzed using descriptive statistics and the Wilcoxon signed-rank test (p ≤0.05). Results indicate a strong preference for careers in state-owned pharmaceutical companies (63.6%) and research and development departments (34%). The seminar significantly enhanced participants’ understanding of pharmacists’ roles, industry complexities, drug development challenges, and regulatory requirements. Notably, 93% of participants reported that the seminar met their expectations and provided valuable insights for future career exploration. These findings underscore the importance of educational interventions in shaping pharmacy students’ career trajectories and aligning their knowledge with the dynamic pharmaceutical industry.</p> Anugerah Budipratama Adina, Alhara Yuwanda, Rizky Farmasita Budiastuti, Nopratilova Nopratilova, Eddy Yusuf, Suk Fei Tan, Saeid Mezail Mawazi, Amelia Herli Copyright (c) 2024 Anugerah Budipratama Adina, Alhara Yuwanda, Rizky Farmasita Budiastuti, Nopratilova Nopratilova, Eddy Yusuf, Suk Fei Tan, Saeid Mezail Mawazi, Amelia Herli https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6791 Fri, 30 Aug 2024 00:00:00 +0000 Integrative Network Pharmacology Unveils Limonia acidissima as a Potential Natural Product for Targeting Cancer https://journal.umpr.ac.id/index.php/bjop/article/view/6988 <p>Cancer remains a formidable health challenge worldwide, with complex molecular mechanisms driving its initiation, progression, and therapeutic resistance. In this study, we employed bioinformatics analyses to elucidate the molecular underpinnings of cancer biology, focusing on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Our GO analysis revealed the enrichment of key biological processes such as protein phosphorylation, regulation of programmed cell death, and transmembrane receptor signaling pathways, underscoring the critical roles of signaling cascades and regulatory mechanisms in tumorigenesis. Similarly, molecular functions such as protein kinase activity and ATP binding were identified as significantly enriched, highlighting the importance of protein kinases and molecular interactions in cancer development and progression. The KEGG pathway analysis further delineated dysregulated signaling pathways associated with cancer, including the MAPK and PI3K-Akt signaling pathways, implicating these pathways as central regulators of cancer progression. These findings deepen our understanding of cancer biology and offer potential targets for therapeutic intervention. Integrating multi-omics data and systems biology approaches may provide deeper insights into the intricate networks underlying cancer pathogenesis, paving the way for developing more effective treatments for cancer patients.</p> Reni Sri Wahyuni, M. Artabah Muchlisin, Ahmad Shobrun Jamil, Engrid Juni Astuti, Agustin Rafikayanti Copyright (c) 2024 Reni Sri Wahyuni, M. Artabah Muchlisin, Ahmad Shobrun Jamil, Engrid Juni Astuti, Agustin Rafikayanti https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/6988 Fri, 30 Aug 2024 00:00:00 +0000 Cover, Content, and Editorial Note from Borneo J Pharm Vol. 7 No. 3 August 2024 https://journal.umpr.ac.id/index.php/bjop/article/view/8442 <p style="text-align: justify;"><em>Assalamu’alaikum Wr. Wb.</em></p> <p style="text-align: justify;">Alhamdulillahirabbil ‘alamin. The next edition of <strong>Borneo Journal of Pharmacy</strong> (<em>Borneo J Pharm</em>), has been published at August 2024. This edition contains ten articles: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Analytical Pharmacy-Medicinal Chemistry, Microbiology Pharmacy, Natural Product Development, Clinical-Community Pharmacy, and Pharmaceutical Education. This edition includes writings from four countries: India, Indonesia, Italy, and Malaysia. The authors come from several institutions, including Universitas Muhammadiyah Malang, Universitas Ahmad Dahlan, Universitas Muhammadiyah Banjarmasin, Universitas Jember, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, University of Kalyani, Azienda Ospedaliero Universitaria Maggiore della Carita, Universitas Airlangga, Institut Ilmu Kesehatan Bhakti Wiyata Kediri, Universitas Islam Bandung, Universitas Mulawarman, Universitas Negeri Yogyakarta, Universitas Gadjah Mada, Universitas Kristen Duta Wacana, Universitas Global Jakarta, and Management and Science University.</p> <p style="text-align: justify;">Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on November 2024.</p> <p style="text-align: justify;"><em>Wassalamu’alaikum Wr. Wb.</em></p> Chief Editor of Borneo J Pharm Copyright (c) 2024 Chief Editor of Borneo J Pharm https://creativecommons.org/licenses/by-sa/4.0 https://journal.umpr.ac.id/index.php/bjop/article/view/8442 Fri, 30 Aug 2024 00:00:00 +0000